Literature DB >> 20391473

Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care.

Michael M Ward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20391473      PMCID： PMC3018780          DOI： 10.1002/acr.20088

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  12 in total

1.  Medicare and drug pricing.

Authors:  John K Iglehart
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

2.  Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.

Authors:  Patricia Neuman; Michelle Kitchman Strollo; Stuart Guterman; William H Rogers; Angela Li; Angie Mae C Rodday; Dana Gelb Safran
Journal:  Health Aff (Millwood)       Date:  2007-08-21       Impact factor: 6.301

3.  Impact of the Medicare Prescription Drug Improvement and Modernization Act on the management of colorectal cancer.

Authors:  Jerry Siegel
Journal:  Am J Health Syst Pharm       Date:  2006-05-01       Impact factor: 2.637

4.  Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis.

Authors:  Jalpa A Doshi; Pengxiang Li; Andrea Puig
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

5.  Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

Authors:  Esi Morgan DeWitt; Henry A Glick; Daniel A Albert; Marshall M Joffe; Frederick Wolfe
Journal:  Arch Intern Med       Date:  2006-01-09

6.  Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.

Authors:  Allan J Wailoo; Nick Bansback; Alan Brennan; Kaleb Michaud; Richard M Nixon; Fred Wolfe
Journal:  Arthritis Rheum       Date:  2008-04

7.  The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?

Authors:  Joeëlle Y Friedman; Lesley H Curtis; Bradley G Hammill; Jatinder K Dhillon; Charles H Weaver; Sugata Biswas; Amy P Abernethy; Kevin A Schulman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

8.  Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.

Authors:  Carolyn R Harley; Jennifer R Frytak; Neeta Tandon
Journal:  Am J Manag Care       Date:  2003-10       Impact factor: 2.229

9.  Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy.

Authors:  Alisa M Shea; Lesley H Curtis; Bradley G Hammill; Lisa D DiMartino; Amy P Abernethy; Kevin A Schulman
Journal:  JAMA       Date:  2008-07-09       Impact factor: 56.272

10.  Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.

Authors:  Jennifer M Polinski; Penny E Mohr; Lorraine Johnson
Journal:  Arthritis Rheum       Date:  2009-06-15
View more
  2 in total

Review 1.  Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.

Authors:  Rafael Ferriols-Lisart; Francisco Ferriols-Lisart
Journal:  Rheumatol Int       Date:  2015-02-01       Impact factor: 2.631

2.  Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.

Authors:  Leslie R Harrold; George W Reed; Joel M Kremer; Jeffrey R Curtis; Daniel H Solomon; Marc C Hochberg; Arthur Kavanaugh; Katherine C Saunders; Ying Shan; Tanya M Spruill; Dimitrios A Pappas; Jeffrey D Greenberg
Journal:  Arthritis Res Ther       Date:  2016-04-26       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.